Pharming Group, the Netherlands-based biopharmaceutical company, has announced significant workforce reductions as part of a broader restructuring effort. On October 6, the company confirmed it will lay off 20% of its non-commercial and non-medical staff, a move aimed at delivering annual cost savings of approximately $10 million.
The layoffs, which impact roles outside of Pharming’s core commercial and medical functions, are part of a plan previously communicated by the company’s leadership. Pharming stated that the restructuring is necessary to streamline operations and position the organization for financial sustainability amidst persistent headwinds in the biopharmaceutical sector.
This decision follows a year marked by similar reduction efforts across the biotech and pharma industries, as companies grapple with tighter financing conditions and increasing pressure to extend cash runways. Pharming’s action echoes a pattern of workforce reductions reported at multiple global companies in 2024 and 2025, reflecting widespread challenges throughout the sector.
Company officials have emphasized that restructuring will not affect ongoing commercial activities or the support provided to patients and healthcare professionals. However, the move highlights the difficult trade-offs faced by mid-sized and specialty pharmaceutical firms seeking to balance growth and long-term viability in a volatile market environment.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!